Hyperpigmentation during interferon-alpha therapy for chronic hepatitis C virus infection

被引:38
|
作者
Willems, M
Munte, K
Vrolijk, JM
Den Hollander, JC
Böhm, M
Kemmeren, MH
De Man, RA
Brouwer, JT
机构
[1] Erasmus Univ Hosp Rotterdam, Dept Hepatogastroenterol, NL-3000 CA Rotterdam, Netherlands
[2] Erasmus Univ Hosp Rotterdam, Dept Pathol, NL-3000 CA Rotterdam, Netherlands
[3] Univ Munster, Dept Dermatol, D-4400 Munster, Germany
[4] Univ Munster, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, D-4400 Munster, Germany
关键词
chronic hepatitis C; combination therapy; hyperpigmentation; interferon-alpha; skin;
D O I
10.1046/j.1365-2133.2003.05422.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Many types of skin disorders concomitantly occur with hepatitis C virus infection. These skin lesions may be induced or worsened during antiviral therapy with interferon-alpha (IFN). To our knowledge, hyperpigmentation of the skin-and especially of the tongue-has not been reported so far. We describe two dark-skinned patients who developed hyperpigmented skin and tongue lesions during combination therapy with IFN and ribavirin. Immunohistochemical analysis of tongue biopsies confirmed the suspicion of melanin deposits in these areas of hyperpigmentation. We hypothesize that during interferon therapy, melanocytes may produce more melanin pigment in the presence of alpha-melanocyte stimulating hormone and sufficient amounts of tyrosine, leading to melanin deposits and clinical hyperpigmentation.
引用
收藏
页码:390 / 394
页数:5
相关论文
共 50 条
  • [1] Systemic sarcoidosis during interferon-alpha therapy for chronic hepatitis C virus infection
    Cacoub, P
    Sbaï, A
    Francès, C
    Génesti, C
    Hausfater, P
    Piette, JC
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2000, 24 (03): : 364 - 366
  • [2] Interferon-alpha treatment of chronic hepatitis C virus infection in children
    Jonas, MM
    Ott, MJ
    Nelson, SP
    Badizadegan, K
    Perez-Atayde, AR
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1998, 17 (03) : 241 - 246
  • [3] Abrupt onset of diabetes during interferon-alpha therapy in patients with chronic hepatitis C
    Recasens, M
    Aguilera, E
    Ampurdanés, S
    Tapias, JMS
    Simó, O
    Casamitjana, R
    Conget, I
    DIABETIC MEDICINE, 2001, 18 (09) : 764 - 767
  • [4] Immunological response in chronic hepatitis C virus infection during interferon alpha therapy
    Panasiuk, A
    Prokopowicz, D
    Zak, J
    HEPATO-GASTROENTEROLOGY, 2004, 51 (58) : 1088 - 1092
  • [5] Variations of serum IgG subclass levels in hepatitis C virus infection during interferon-alpha therapy
    Musset, L
    Ghillani, P
    Lunel, F
    Cacoub, P
    Cresta, P
    Frangeul, L
    Rosenheim, M
    Preudhomme, JL
    IMMUNOLOGY LETTERS, 1997, 55 (01) : 41 - 45
  • [6] Tongue hyperpigmentation during interferon-alpha and ribavirin therapy
    Aguayo-Leiva, Ingrid
    Perez, Bibiana
    Salguero, Irene
    Jaen, Pedro
    EUROPEAN JOURNAL OF DERMATOLOGY, 2009, 19 (03) : 291 - 292
  • [7] Interferon-alpha and hepatitis C virus: the skin matters
    Floristan, U.
    Feltes, R.
    Ramirez-Marin, P.
    Herranz-Pinto, P.
    REVISTA CLINICA ESPANOLA, 2011, 211 (02): : 92 - 97
  • [8] INTERFERON-ALPHA RETREATMENT IN CHRONIC HEPATITIS-C
    GERKEN, G
    TEUBER, G
    GOERGEN, B
    HERMANN, K
    ZUMBUSCHENFELDE, KHM
    JOURNAL OF HEPATOLOGY, 1995, 22 : 118 - 121
  • [9] LOSS OF HBSAG WITH INTERFERON-ALPHA THERAPY IN CHRONIC HEPATITIS-D VIRUS-INFECTION
    LAU, JYN
    KING, R
    TIBBS, CJ
    CATTERALL, AP
    SMITH, HM
    PORTMANN, BC
    ALEXANDER, GJM
    WILLIAMS, R
    JOURNAL OF MEDICAL VIROLOGY, 1993, 39 (04) : 292 - 296
  • [10] Takotsubo cardiomyopathy and transient thyrotoxicosis during combination therapy with interferon-alpha and ribavirin for chronic hepatitis C
    Carmen Sorina Martin
    Luminita Nicoleta Ionescu
    Carmen Gabriela Barbu
    Anca Elena Sirbu
    Ioana Maria Lambrescu
    Ioana Smarandita Lacau
    Doina Ruxandra Dimulescu
    Simona Vasilica Fica
    BMC Endocrine Disorders, 14